WellDoc’s Series B totals $22M

December 21, 2015

Share:

Healthtech company WellDoc has raised a $22 million Series B round co-led by Samsung Ventures and Merck Global Health Innovation Fund. Proceeds from the financing will go toward continued commercialization and adoption efforts for BlueStar, the company’s flagship product that enables patients with type 2 diabetes to self-manage through real-time motivational, behavioral and educational coaching.